CLS strengthens its position in the US
During the past year, Clinical Laserthermia System has advanced its position in the urology segment on the US market. A number of agreements have...
Great interest in Dicot’s LIB-01
Many interested parties are keeping an eye on the development of LIB-01, Dicot's drug candidate for the treatment of erectile dysfunction, and the interest...
Promore carries out reverse acquisition and changes its operations
Solna-based Promore Pharma has been in voluntary liquidation since mid-October. The liquidator now seems to have found a solution, which means that the company...
Chordate installs system in Germany and launches in the UAE
Chordate Medical has secured an agreement for the installation of the migraine treatment Ozilia at a private specialist clinic in Germany. This follows from...
CAR T deal puts spotlight on Elicera’s technology
Is the hype around CAR T-cell therapies real? A recent licensing agreement struck between Legend Biotech and Novartis to advance novel CAR T candidates...
Curasight CEO: “Working on accelerated plan for uTREAT”
Looking back at the third quarter, it’s clear that Curasight is keeping the momentum in the development. Among other things, the much-anticipated phase II...
Prolight’s CEO: ”Proof-of-Performance in whole blood important milestone”
Prolight Diagnostics has demonstrated Proof-of-Performance in whole blood for its digital test system Psyros. It is already known that the system performs as promised...
Ultimovacs CEO: “Data could put us at the forefront of cancer...
Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO...
Scandions CMO: “Our overall survival data are quite impressive”
Scandion Oncologys läkemedelskandidat SCO-101 utvärderas för närvarande i fas II-studien CORIST för behandling av kemoterapiresistent metastaserad tjocktarmscancer. I veckan kunde bolaget meddela positiva data...
Saniona’s CEO: ”Selectivity is the cornerstone of future epilepsy treatments”
On Tuesday morning Saniona was able to announce advancements in its Kv7-programme. The company has now concluded the lead optimisation phase and the programme...
